Kenvue Inc. (NYSE:KVUE) Stock Has Consensus Price Target of $19.33 According to Brokerages

Shares of Kenvue Inc. (NYSE:KVUE) have received a consensus rating of “Hold” from the thirteen ratings firms that are currently covering the company, Marketbeat reports. Thirteen investment analysts have rated the stock with a hold recommendation. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $19.33.

A number of research analysts have weighed in on the stock. Barclays lifted their price target on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. UBS Group lowered their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Weiss Ratings restated a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. HSBC cut their price objective on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Finally, Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th.

Trending Headlines about Kenvue

Here are the key news stories impacting Kenvue this week:

• Positive Sentiment: Revenue increased 3.2% year over year to $3.89 billion, exceeding the roughly $3.86 billion consensus estimate. Management cited continued growth in Self Care and Essential Health, productivity initiatives, margin expansion and strong cash generation. Kenvue Reports Third Quarter 2026 Results
• Positive Sentiment: Reported earnings were $0.29 per share, up from $0.28 a year earlier. Zacks characterized the result as slightly ahead of its $0.28 consensus estimate, while other coverage said profit fell short of expectations, suggesting the market is focused on the exact earnings measure and guidance. Kenvue Surpasses Q3 Earnings Estimates
• Positive Sentiment: The quarterly performance represents Kenvue’s fourth consecutive quarter of net and organic sales growth, supporting management’s efforts to rebuild momentum across its consumer-health brands. Kenvue Profit, Revenue Rise as Turnaround Efforts Continue
• Neutral Sentiment: Kenvue’s results arrive as its approximately $40 billion acquisition by Kimberly-Clark approaches closing. The deal may provide strategic support, but investors remain focused on execution, integration and the turnaround’s durability. Kenvue Q3 2026 Revenue Beats as Kimberly-Clark Deal Nears Close
• Negative Sentiment: The conflicting earnings headlines indicate that profit performance did not clearly exceed investor expectations, even though revenue beat forecasts. Earlier concerns about inflation and cautious consumer spending also remain potential pressures on margins and demand. Kenvue Misses Third-Quarter Profit Expectations

Kenvue Trading Down 1.5%

NYSE:KVUE opened at $19.26 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The business’s 50-day simple moving average is $18.40 and its 200-day simple moving average is $18.19. Kenvue has a fifty-two week low of $14.06 and a fifty-two week high of $20.13. The stock has a market capitalization of $36.99 billion, a PE ratio of 22.14, a price-to-earnings-growth ratio of 1.79 and a beta of 0.48.

Kenvue (NYSE:KVUE) last posted its earnings results on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.29. The business had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.86 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. Kenvue’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.28 EPS. Sell-side analysts expect that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were paid a $0.21 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is currently 96.55%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Kenvue during the 2nd quarter worth approximately $2,882,279,000. Pentwater Capital Management LP bought a new stake in Kenvue in the 2nd quarter valued at $977,094,000. HBK Investments L P grew its holdings in Kenvue by 33.3% in the 2nd quarter. HBK Investments L P now owns 28,000,001 shares of the company’s stock valued at $535,080,000 after buying an additional 7,000,000 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Kenvue by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 22,270,175 shares of the company’s stock valued at $383,938,000 after buying an additional 196,981 shares in the last quarter. Finally, Amundi grew its holdings in Kenvue by 41.2% in the 2nd quarter. Amundi now owns 18,483,326 shares of the company’s stock valued at $353,216,000 after buying an additional 5,392,413 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Kenvue

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.